Cardiac Amyloidosis: ATTR vs AL Diagnosis, PYP Scintigraphy, Genetic Testing, and Stage-Based Therapy
Comprehensive evidence-based guideline for diagnosis and management of cardiac amyloidosis in adults — from clinical clues and red flags through PYP scintigraphy, mandatory monoclonal protein workup, ATTR genotyping, biopsy indications, and stage-specific disease-modifying therapy with tafamidis, patisiran, and AL chemotherapy.
Executive Summary
Cardiac amyloidosis is an under-recognized cause of HFpEF, restrictive cardiomyopathy, and unexplained left ventricular hypertrophy that is now treatable when diagnosed early. The two clinically dominant subtypes are ATTR amyloidosis (transthyretin — wild-type ATTRwt in elderly males or hereditary ATTRv) and AL amyloidosis (immunoglobulin light chain from a plasma cell dyscrasia). Diagnosis follows a fixed sequence: (1) recognize red flags — discordant LV wall thickness greater than ECG voltage, low-flow low-gradient aortic stenosis, bilateral carpal tunnel syndrome years before HF, lumbar spinal stenosis, autonomic neuropathy, polyneuropathy, biceps tendon rupture; (2) mandatory monoclonal protein workup with serum and urine immunofixation plus serum free light chain ratio — abnormal results require hematology referral and tissue biopsy; (3) if monoclonal workup is negative, technetium-99m PYP (or DPD/HMDP) bone scintigraphy with Perugini grade 2 or 3 myocardial uptake is diagnostic of ATTR cardiac amyloidosis without biopsy; (4) ATTR diagnosis mandates TTR gene sequencing to distinguish wild-type from variant disease (e.g., V122I in 3–4% of African ancestry) and screen at-risk relatives. Treatment is subtype-specific: AL requires urgent hematologic therapy (daratumumab–CyBorD induction, autologous stem cell transplant in eligible patients), ATTR is managed with the TTR stabilizer tafamidis 61 mg PO daily (ATTR-ACT trial — 30% mortality reduction over 30 months) or TTR gene silencers (patisiran, vutrisiran, eplontersen) for ATTRv with polyneuropathy. Heart failure management requires careful diuresis, avoidance of beta-blockers and ACEi/ARB if hypotensive, and cautious anticoagulation given the high stroke risk despite sinus rhythm. Mayo and NAC staging predicts survival and guides intensity of therapy.
1. Subtypes, Pathophysiology, and Epidemiology
The Two Clinically Dominant Subtypes
Cardiac amyloidosis results from extracellular deposition of misfolded protein fibrils that disrupt myocardial architecture, increase stiffness, and impair both systolic and diastolic function. Although more than 30 amyloidogenic precursor proteins exist, two account for nearly all cardiac cases:
- ATTR amyloidosis — transthyretin (formerly prealbumin), produced primarily by the liver as a tetramer that transports thyroxine and retinol-binding protein. Misfolding and dissociation generate amyloidogenic monomers. Two forms:
- ATTRwt (wild-type) — formerly “senile cardiac amyloidosis”; idiopathic age-related misfolding of normal TTR. Predominant in men over 65; mean age at diagnosis 75. Estimated 13–17% prevalence in HFpEF over 60, and 16% in low-flow low-gradient aortic stenosis.
- ATTRv (variant or hereditary) — autosomal dominant TTR mutations. Over 130 known pathogenic variants. Most common in Western practice: V122I (Val122Ile, present in 3–4% of African ancestry, manifests after age 60 with cardiomyopathy); T60A (Irish/UK lineage); V30M (Portuguese/Swedish/Japanese, classic familial amyloid polyneuropathy).
- AL amyloidosis — immunoglobulin light chain (lambda more often than kappa) produced by an underlying plasma cell dyscrasia (often small, often without overt myeloma). Median age 65 but ranges 40–80. AL is rapidly fatal without treatment; cardiac involvement in 50–75% of AL cases drives prognosis.
Less Common Subtypes
- AA amyloidosis — secondary to chronic inflammation (RA, IBD, FMF, chronic infection); rarely cardiac dominant
- AApoAI / AApoAII — apolipoprotein variants, very rare
- Localized cardiac amyloidosis — atrial natriuretic peptide deposition in atria of elderly; clinical significance limited
Mechanism of Myocardial Dysfunction
Amyloid fibrils accumulate between cardiomyocytes, in the interstitium, and around vessels, producing a thick, stiff, non-compliant ventricle with preserved or near-preserved ejection fraction (HFpEF phenotype) but markedly impaired longitudinal strain, restrictive filling, and biatrial enlargement. Coronary microvascular involvement causes angina without obstructive epicardial disease. AL light chains additionally exert direct toxicity on cardiomyocytes (oxidative stress, lysosomal dysfunction), explaining why AL has more rapid hemodynamic deterioration and worse prognosis stage-for-stage than ATTR despite less amyloid burden by volume. Autonomic and somatic nerve infiltration produces orthostatic hypotension, gastroparesis, erectile dysfunction, and small-fiber neuropathy.
At-Risk Populations and Screening Triggers
| Phenotype | Estimated amyloidosis prevalence | Recommended workup |
|---|---|---|
| HFpEF age >60 with LV wall >12 mm | 13–17% | Monoclonal workup + PYP scan if monoclonal negative |
| Low-flow, low-gradient aortic stenosis | ~16% | Same — esp. before TAVR planning |
| Unexplained LVH age >65 (no HTN history) | 20–30% | Same; consider HCM gene panel if also young |
| Bilateral carpal tunnel + HF or LVH | ~50% | Mandatory amyloid workup |
| Lumbar spinal stenosis + HF or LVH | 30–40% | Mandatory amyloid workup |
| Bicep tendon rupture + cardiac symptoms | Increased | Consider amyloid workup |
| Family history of TTR amyloidosis | 50% (if first-degree relative carrier) | Genetic counseling + TTR sequencing |
2. Clinical Red Flags and Initial Imaging
Cardiac Red Flags
- HFpEF in a patient without typical risk factors (especially elderly males)
- LV wall thickness greater than 12 mm with low ECG voltage (Sokolow-Lyon less than 1.5 mV) — voltage-mass discordance is the single most useful red flag
- Pseudoinfarct pattern on ECG (Q waves in V1–V3 without coronary occlusion)
- Conduction disease — first-degree AV block, bifascicular block, complete heart block
- Atrial fibrillation in the absence of valvular disease, especially with biatrial enlargement
- Low-flow low-gradient aortic stenosis with paradoxically preserved EF
- Restrictive filling pattern on echo (E/A >2, deceleration time <160 ms)
- Apical sparing pattern of longitudinal strain (“cherry on top”) — relative apex preservation with severe basal/mid-ventricular dysfunction
- Pericardial effusion (small to moderate) without clear etiology
- Disproportionate elevation of NT-proBNP for symptom severity
- Persistent troponin elevation without acute coronary syndrome
Extra-Cardiac Red Flags
- Carpal tunnel syndrome — bilateral, frequently 5–10 years before cardiac symptoms
- Lumbar spinal stenosis
- Spontaneous biceps tendon rupture (Popeye sign)
- Polyneuropathy (length-dependent, sensory predominant)
- Autonomic dysfunction — orthostatic hypotension, erectile dysfunction, gastroparesis
- Macroglossia (AL only — pathognomonic when present, but uncommon)
- Periorbital purpura — “raccoon eyes” (AL only)
- Nephrotic-range proteinuria (AL more often than ATTR)
- Hepatomegaly with elevated alkaline phosphatase, no hepatic mass
ECG Voltage-Mass Discordance
Although classically described, low ECG voltage occurs in only 30–40% of cardiac amyloidosis. The more sensitive finding is voltage that is inappropriately low for the degree of LVH. Calculate the ratio of Sokolow-Lyon voltage (S in V1 + R in V5 or V6) to LV mass index — values below 1.5 mV with septal thickness >12 mm strongly suggest infiltrative disease. Pseudoinfarct Q waves in anterior precordial leads occur in 50% and result from amyloid-replaced myocardium rather than infarction.
Echocardiography
| Finding | Significance | Limitation |
|---|---|---|
| LV wall thickness >12 mm (often >15 mm) | Suggests infiltrative cardiomyopathy | Overlaps with HCM, hypertensive heart disease |
| Granular sparkling myocardial echotexture | Classic but operator-dependent and modern transducers reduce sensitivity | Now considered nonspecific |
| Biatrial enlargement disproportionate to AF | Restrictive physiology | Also seen in chronic AF, MS |
| RV wall thickening >6 mm | Suggests amyloidosis (HCM rarely affects RV) | Useful discriminator |
| Apical sparing on global longitudinal strain | Relative apex strain preservation; bullseye plot diagnostic | Best discriminator from other LVH causes; operator-dependent |
| Restrictive mitral inflow (E/A >2) | Late-stage finding | Insensitive early |
| Low LV outflow tract velocity time integral | Low-flow state | May coexist with low-gradient AS |
| Small to moderate pericardial effusion | Common but nonspecific | Tamponade rare |
Cardiac MRI
Cardiac MRI provides high sensitivity but cannot distinguish amyloid subtype. Characteristic findings:
- Diffuse subendocardial late gadolinium enhancement (LGE) not following coronary territory — pathognomonic
- Difficulty nulling the myocardium on look-locker sequences (myocardium nulls before or simultaneously with blood pool)
- Markedly elevated extracellular volume (ECV) — values >0.40 highly suggestive (normal <0.30)
- Native T1 mapping >1100 ms (vendor-dependent thresholds)
- Atrial wall LGE in advanced disease
3. Mandatory Monoclonal Workup First
The Diagnostic Sequence is Fixed
Critical principle: monoclonal protein workup MUST precede PYP scan
PYP scintigraphy can be falsely positive in AL amyloidosis (5–20% of AL cases show some myocardial uptake) and a positive PYP scan in a patient with undiagnosed AL can lead to fatal misdiagnosis as ATTR with delayed AL treatment. AL amyloidosis is far more aggressive, with median survival of 6 months for stage IV without treatment. Always exclude AL before declaring ATTR.
Three-Test Monoclonal Workup
| Test | What it detects | Sensitivity for AL |
|---|---|---|
| Serum immunofixation electrophoresis (SIFE) | Monoclonal IgG, IgA, IgM heavy chain or free light chain | ~75% |
| Urine immunofixation electrophoresis (UIFE) (24-hour collection or random with creatinine) | Bence Jones protein | ~70% |
| Serum free light chain (sFLC) assay with kappa/lambda ratio | Free light chain excess; abnormal ratio <0.26 or >1.65 (renal-adjusted: <0.37 or >3.1 if eGFR reduced) | ~95% |
The combination of all three tests has greater than 99% sensitivity for plasma cell dyscrasia. Any positive result mandates hematology referral and tissue biopsy; do not proceed to PYP without a complete monoclonal workup.
Hematology Referral and Bone Marrow Biopsy
An abnormal monoclonal workup requires:
- Hematology consultation
- Bone marrow biopsy with aspirate, flow cytometry, and Congo red staining
- Skeletal survey or PET/CT for myeloma evaluation
- Beta-2 microglobulin, calcium, creatinine, LDH
- If amyloid is found in bone marrow or another biopsy site, mass spectrometry (laser capture microdissection with liquid chromatography-tandem MS — LC-MS/MS) confirms the precursor protein (AL kappa, AL lambda, or ATTR contamination)
What if Monoclonal Workup is Equivocal?
Monoclonal gammopathy of undetermined significance (MGUS) is present in 3–5% of adults over 50 and 10% over 75 — coincidental MGUS in a patient with cardiac amyloidosis does not exclude ATTR. The discriminator is tissue typing by mass spectrometry. If sFLC ratio is borderline abnormal but no M-spike on SIFE/UIFE and clinical pattern strongly suggests ATTR (e.g., elderly male, bilateral carpal tunnel, V122I ethnic background), proceed with PYP scan but pursue tissue biopsy if PYP is grade 1 or equivocal. Hematology should always be involved when monoclonal workup is positive.
4. PYP Scintigraphy and Tissue Biopsy
Technetium-99m PYP/DPD/HMDP Bone Scintigraphy
Bone-avid radiotracers (99mTc-pyrophosphate in the US, 99mTc-DPD or HMDP in Europe) bind to ATTR amyloid fibrils with high specificity, producing distinctive myocardial uptake. The Perugini grading system is used:
| Perugini grade | Visual finding (3-hour planar) | Interpretation |
|---|---|---|
| Grade 0 | No myocardial uptake; ribs visible | ATTR very unlikely (sensitivity ~99% if grade 0) |
| Grade 1 | Myocardial uptake less than rib uptake | Equivocal — biopsy required |
| Grade 2 | Myocardial uptake equal to rib uptake | Diagnostic of ATTR (specificity >95% IF monoclonal workup negative) |
| Grade 3 | Myocardial uptake greater than rib uptake | Diagnostic of ATTR (specificity >95% IF monoclonal workup negative) |
SUV Ratio (Quantitative)
SPECT/CT permits quantitative analysis with the heart-to-contralateral-lung (H/CL) ratio measured on planar imaging at 1 hour:
- H/CL >1.5 at 1 hour highly suggestive of ATTR
- H/CL >1.0 at 3 hours diagnostic when paired with grade 2–3 visual uptake
- SPECT confirms myocardial (rather than blood pool) localization — essential because planar grade 2 uptake from blood pool can be misclassified as myocardial
Non-Biopsy Diagnostic Pathway
The Gillmore criteria allow non-invasive diagnosis of ATTR cardiac amyloidosis when ALL of the following are met:
- Heart failure or cardiac findings consistent with amyloidosis
- Echocardiographic or CMR findings consistent with amyloidosis
- Perugini grade 2 or 3 myocardial uptake on PYP/DPD/HMDP scan
- Negative serum and urine immunofixation AND normal serum free light chain ratio
If all four criteria are met, the specificity for ATTR exceeds 99% and biopsy is not required. If any criterion is not met, tissue biopsy is mandatory.
Tissue Biopsy Indications
| Scenario | Required biopsy | Rationale |
|---|---|---|
| Any positive monoclonal workup | Bone marrow + abdominal fat pad (or affected organ); endomyocardial if extracardiac negative | Confirm AL and identify subtype |
| PYP grade 1 or equivocal | Endomyocardial biopsy | Insufficient for non-invasive diagnosis |
| PYP grade 0 with strong clinical suspicion | Endomyocardial biopsy | Rare AL or non-TTR amyloid possible |
| Clinical-imaging discordance | Endomyocardial biopsy | Rule out other infiltrative diseases |
Histology and Subtyping
Congo red staining shows apple-green birefringence under polarized light — this confirms amyloid but does not identify the precursor protein. Mass spectrometry (LC-MS/MS on laser-capture-microdissected Congo-red-positive tissue) identifies the exact protein and is now the gold standard for amyloid typing. Immunohistochemistry with anti-TTR, anti-kappa, anti-lambda, and anti-AA antibodies may be used in centers without mass spectrometry but is less reliable.
TTR Gene Sequencing After ATTR Diagnosis
Every patient with confirmed ATTR cardiac amyloidosis requires TTR sequencing — even if “obviously” wild-type by age and ethnicity. Approximately 5–10% of patients clinically suspected of ATTRwt actually carry a variant. Confirmation of:
- ATTRwt — no further genetic action; family screening unnecessary
- ATTRv — first-degree relatives offered genetic counseling and TTR sequencing; carrier siblings/children may benefit from baseline cardiac and neurologic evaluation, with periodic surveillance for disease onset
5. ATTR Disease-Modifying Therapy
Treatment Selection by Subtype and Phenotype
| Diagnosis | First-line disease-modifying therapy | Mechanism |
|---|---|---|
| ATTRwt cardiac amyloidosis | Tafamidis 61 mg PO daily (or acoramidis 800 mg BID) | TTR tetramer stabilizer — prevents dissociation |
| ATTRv with cardiomyopathy (no/mild PN) | Tafamidis 61 mg PO daily OR vutrisiran 25 mg SC q3mo | Stabilizer or hepatic TTR mRNA silencer |
| ATTRv with polyneuropathy (with/without CM) | Patisiran 0.3 mg/kg IV q3wk OR vutrisiran 25 mg SC q3mo OR eplontersen 45 mg SC monthly | siRNA or ASO — silence TTR production |
| AL cardiac amyloidosis | Daratumumab + CyBorD (cyclophosphamide-bortezomib-dexamethasone) induction | Suppress plasma cell light chain production; ASCT in eligible patients |
Tafamidis — ATTR-ACT Pivotal Trial
The ATTR-ACT trial (NEJM 2018) randomized 441 patients with ATTR cardiomyopathy to tafamidis (80 mg or 20 mg) vs placebo for 30 months. Pooled tafamidis reduced all-cause mortality by 30% (HR 0.70) and cardiovascular hospitalizations by 32%. Benefits emerged at approximately 18 months and increased over time. Open-label extension confirms continued separation of survival curves through 60 months. The 80 mg dose (now reformulated as tafamidis meglumine 61 mg once daily, equivalent to 80 mg tafamidis acid) is the FDA-approved dose. Tafamidis is well tolerated; no significant adverse events vs placebo. Cost is the principal limitation (US list price ~$200,000/year).
Acoramidis (Newer TTR Stabilizer)
Acoramidis is a near-complete TTR stabilizer that achieved a clinically and statistically significant reduction in the composite of all-cause mortality and cardiovascular hospitalization at 30 months in the ATTRibute-CM trial. Dose: 800 mg PO BID. FDA approved 2024. Direct comparison with tafamidis lacking; both are reasonable first-line stabilizers.
TTR Silencers — Indications and Use
| Drug | Mechanism | Dose / route | Approved indication |
|---|---|---|---|
| Patisiran | siRNA in lipid nanoparticle; reduces hepatic TTR ~80% | 0.3 mg/kg IV every 3 weeks; premedication required (steroid + antihistamine + acetaminophen) | ATTRv polyneuropathy; cardiac use under investigation |
| Vutrisiran | Next-generation siRNA, GalNAc-conjugated, longer-acting | 25 mg SC every 3 months | ATTRv polyneuropathy; HELIOS-B showed cardiac benefit including in ATTRwt |
| Eplontersen | Antisense oligonucleotide GalNAc-conjugated | 45 mg SC monthly self-administered | ATTRv polyneuropathy; CARDIO-TTRansform pending |
NAC Staging and Prognosis
The UK National Amyloidosis Centre (NAC) staging system stratifies ATTR cardiac amyloidosis prognosis using two biomarkers:
- Stage I — NT-proBNP ≤3000 ng/L AND eGFR ≥45 mL/min/1.73m². Median survival ~70 months.
- Stage II — NT-proBNP >3000 OR eGFR <45 (but not both). Median survival ~47 months.
- Stage III — NT-proBNP >3000 AND eGFR <45. Median survival ~24 months.
Tafamidis benefit is preserved across NAC stages but advanced stage (NYHA IV, NAC III with severe disease) shows attenuated benefit; some clinicians defer initiation in moribund patients given cost and slow onset of action.
AL-Specific Considerations Before ATTR Therapy
If AL is identified, ATTR-directed therapy (tafamidis, acoramidis, TTR silencers) is contraindicated and inappropriate. AL must be treated with hematologic regimens (next section).
Practice Insights: Cardiac Amyloidosis — AL Exclusion FIRST, PYP Scintigraphy for ATTR, and Tafamidis Era
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A PYP scan ordered before light chains are excluded can label AL amyloidosis as ATTR and cost the patient the only treatment that works — (1) AL amyloidosis must be EXCLUDED FIRST with immunofixation + free light chains before PYP scintigraphy (PYP can be falsely positive in AL); (2) PYP scintigraphy is non-invasive diagnostic for ATTR when AL excluded — replacing biopsy for most cases; (3) tafamidis 61 mg daily for ATTR-CM has transformed prognosis per ATTR-ACT NEJM 2018 — initiated in any Stage I-II patient. The “biopsy required for all amyloid” era has ended.
AL exclusion FIRST: serum + urine immunofixation + free light chains
Before any PYP scintigraphy, screen for AL amyloidosis: serum AND urine immunofixation electrophoresis (SIFE + UIFE) + serum free light chains (kappa + lambda + K/L ratio). The reason: PYP scintigraphy can be falsely positive in AL amyloidosis, leading to missed AL diagnosis and inappropriate treatment. If AL screen positive (abnormal IFE, abnormal K/L ratio > 1.65 or < 0.26), proceed to hematology workup (bone marrow biopsy, serum/urine M-spike, Congo red staining of tissue). AL amyloidosis is an oncology emergency — treat the underlying plasma cell dyscrasia with daratumumab-based regimens (Dara-CyBorD per ANDROMEDA NEJM 2021). If AL screen NEGATIVE, proceed to PYP scintigraphy.
PYP scintigraphy: non-invasive diagnostic for ATTR (95% specificity if AL excluded)
99mTc-pyrophosphate (PYP) scintigraphy is the non-invasive diagnostic gold standard for ATTR cardiac amyloidosis when AL has been excluded. Grading: Grade 0 (negative, no uptake), Grade 1 (equivocal, mild uptake less than bone), Grade 2 (moderate uptake equal to bone), Grade 3 (intense uptake greater than bone). Quantitative heart/contralateral lung ratio (H/CL) ≥ 1.5 at 1 hour confirms diagnosis. Grade 2-3 PYP with negative AL screen = ATTR cardiac amyloidosis with 95% specificity — biopsy no longer needed for most cases. Endomyocardial biopsy reserved for ambiguous PYP (Grade 1), positive AL screen with negative bone marrow, atypical features.
Genetic testing for hATTR after ATTR confirmed
After ATTR confirmed by PYP, send genetic testing for hereditary ATTR (hATTR) mutations. Common variants: Val122Ile in African-Americans (3-4% population prevalence — important to test, often missed!), Val30Met (endemic in Portugal, Sweden, Japan), T60A (Ireland). Wild-type ATTR (wtATTR — formerly “senile cardiac amyloidosis”) is the most common in elderly white men — no mutation, but treatment same as hATTR for cardiomyopathy. Mutation identification has 2 implications: (1) drives screening of first-degree relatives (autosomal dominant inheritance); (2) opens treatment options including patisiran/inotersen for hATTR-PN (polyneuropathy).
Tafamidis 61 mg daily for ATTR-CM — Mayo Stage-driven initiation
Tafamidis (Vyndaqel 80 mg or Vyndamax 61 mg PO daily) is a TTR kinetic stabilizer with STRONG evidence from ATTR-ACT NEJM 2018: 30% reduction in all-cause mortality + cardiovascular hospitalization at 30 months in wtATTR/hATTR-CM. Experienced clinicians initiate tafamidis in any Mayo Stage I-II patient with good functional status. Stage III patients (NT-proBNP > 3000 + troponin T > 0.05) have lower response rates but still considered. Acoramidis (Attruby, FDA 2024) is alternative per ATTRibute-CM. Vutrisiran (Amvuttra, FDA 2024 for ATTR-CM per HELIOS-B) is SC q 3 months siRNA — important option for tafamidis nonresponders. Avoid: ACE/ARB, beta-blockers (autonomic insufficiency, hypotension in amyloidosis); use loop diuretics carefully (sensitive to depletion); anticoagulation for AF or LV thrombus (intracardiac thrombus risk despite preserved EF).
Anonymized Case: wtATTR-CM with Bilateral Carpal Tunnel Hint → Tafamidis Treatment
A man in his late seventies (no diabetes, mild HTN on amlodipine) presented with progressive exertional dyspnea over 6 months, fatigue, and bilateral lower-extremity edema. Past medical history significant for bilateral carpal tunnel syndrome treated surgically 5 years prior (RED FLAG — bilateral CTS often precedes ATTR cardiac symptoms by years). Vital signs: HR 78, BP 118/74 (relatively low for prior HTN — suggesting reduced cardiac output), RR 18. Exam: bilateral basilar crackles, S4 gallop, mild ankle edema. ECG: low voltage in limb leads despite LV hypertrophy on echo. Echocardiogram: LVEF 55% (preserved); LV wall thickness 14 mm (concentric); apical-sparing global longitudinal strain pattern (“cherry on top” — strongly suggestive of cardiac amyloid); biatrial enlargement; restrictive diastolic dysfunction. Laboratory: NT-proBNP 5,200 pg/mL (very elevated for preserved EF), troponin T 0.08 ng/mL (mildly elevated), Cr 1.1, normal liver function. AL screen FIRST: serum immunofixation negative, urine immunofixation negative, serum free light chains kappa 18, lambda 14, K/L ratio 1.29 (NORMAL — AL excluded). 99mTc-PYP scintigraphy: Grade 3 uptake, heart/contralateral lung ratio 1.8 at 1 hour — strongly positive for ATTR cardiac amyloidosis. Diagnosis: ATTR-CM with AL excluded. Genetic testing: wtATTR (wild-type, no mutation — family screening not needed). Mayo Stage III (NT-proBNP > 3000 + troponin T > 0.05). Treatment: tafamidis 61 mg PO daily initiated. Loop diuretic furosemide 20 mg daily for fluid management (low dose, careful titration to avoid depletion). Discontinued amlodipine and avoided ACE-I/beta-blocker (autonomic instability risk in cardiac amyloid). 12-month follow-up: NYHA II (improved from III), NT-proBNP decreased to 3,200, no HF hospitalization, sustained on tafamidis. New atrial fibrillation diagnosed on Holter monitor — initiated apixaban 5 mg BID for stroke prevention (intracardiac thrombus risk in amyloid despite preserved EF).
Four Protocol Deviations Seasoned Clinicians Now Default To
- AL exclusion FIRST: serum + urine immunofixation + free light chains (K/L ratio). PYP can be falsely positive in AL. If AL screen positive → hematology workup (bone marrow, M-spike, Congo red) + oncology-emergency treatment (Dara-CyBorD per ANDROMEDA). If AL negative → PYP.
- PYP scintigraphy Grade 2-3 + AL excluded = ATTR (95% specificity, biopsy avoided). H/CL ratio ≥ 1.5 at 1h confirms. Grade 1 equivocal → consider biopsy. Biopsy reserved for ambiguous PYP, positive AL with negative marrow, atypical features.
- Genetic testing after ATTR confirmed. Val122Ile in African-Americans (3-4% prevalence, frequently missed), Val30Met endemic (Portugal/Sweden/Japan), T60A (Ireland), wtATTR (no mutation, elderly white men). Drives family screening for hATTR + opens hATTR-PN treatment options.
- Tafamidis 61 mg daily for ATTR-CM at Mayo Stage I-II — initiate promptly. ATTR-ACT NEJM 2018: 30% mortality + HF hospitalization reduction. Acoramidis alternative (ATTRibute-CM, FDA 2024). Vutrisiran for tafamidis nonresponders (HELIOS-B). AVOID ACE/ARB/beta-blockers (autonomic instability). Anticoagulation for AF or LV thrombus despite preserved EF.
6. AL Therapy, HF Management, and Special Considerations
AL Amyloidosis — Urgent Hematology Treatment
Treatment intensity depends on Mayo 2012 staging using cardiac biomarkers (NT-proBNP, troponin T or I) and free light chain difference:
| Mayo 2012 stage | Definition | Median OS untreated |
|---|---|---|
| Stage I | 0 of 3 markers above threshold | ~94 months |
| Stage II | 1 marker above | ~40 months |
| Stage III | 2 markers above | ~14 months |
| Stage IV | 3 markers above (NT-proBNP >1800, troponin elevated, dFLC >180) | ~6 months |
Standard induction (ANDROMEDA trial) is daratumumab + cyclophosphamide + bortezomib + dexamethasone (Dara-CyBorD) for 6 cycles. Hematologic complete response (negative immunofixation, normal sFLC ratio) is the goal; achievement predicts cardiac and renal response and improved survival. Autologous stem cell transplant (ASCT) is reserved for younger fit patients (typically <70 years, ECOG 0–2, NT-proBNP <5000, no severe cardiac involvement) — Mayo Clinic transplant eligibility criteria. Cardiac response (NT-proBNP reduction >30% with absolute value <300) is associated with substantial survival benefit.
Heart Failure Management — Unique Principles
| Drug class | Use in cardiac amyloidosis | Caveat |
|---|---|---|
| Loop diuretics (furosemide, torsemide) | Cornerstone for congestion | Aggressive titration; orthostasis common from autonomic neuropathy |
| MRA (spironolactone) | Useful for fluid management, low-dose 12.5–25 mg | Watch K, especially with ACEi/ARB and CKD |
| ACEi / ARB / ARNI | Generally poorly tolerated | Hypotension common; many patients require discontinuation |
| Beta-blockers | Avoid or use very low dose | Negative inotropy in restrictive heart with fixed stroke volume causes worsening output and orthostatic hypotension; preserved heart rate is needed for cardiac output |
| Calcium channel blockers (verapamil, diltiazem) | AVOID | Bind avidly to amyloid; can precipitate complete heart block and cardiogenic shock |
| Digoxin | AVOID | Binds to amyloid fibrils; toxicity at therapeutic levels |
| SGLT2 inhibitors (dapagliflozin, empagliflozin) | Reasonable in HFpEF/HFrEF, including amyloidosis | Modest data in amyloidosis; benefit likely class effect for HF |
Atrial Fibrillation and Anticoagulation
AF prevalence in cardiac amyloidosis exceeds 50%, and the stroke risk from atrial mechanical dysfunction is high even in sinus rhythm. Thrombus formation in the left atrial appendage occurs in 30% of AF patients with amyloidosis even when therapeutically anticoagulated. Strategy:
- Anticoagulate any patient with AF or atrial flutter regardless of CHA2DS2-VASc score — apixaban 5 mg BID preferred
- TEE before cardioversion mandatory regardless of AC duration (high LAA thrombus prevalence)
- Rate control challenging — beta-blockers and CCBs poorly tolerated; consider amiodarone for both rate and rhythm control
- Catheter ablation feasible in selected patients but recurrence rate higher than non-amyloid AF
- Consider oral anticoagulation in advanced cardiac amyloidosis with biatrial enlargement even in sinus rhythm — recommendations are evolving
Conduction Disease and Devices
Conduction disease (first-degree AV block, bifascicular block, complete heart block) is common and progressive. Pacemaker indications follow standard guidelines but the threshold for prophylactic device placement is lower in advanced amyloidosis. Implantable cardioverter-defibrillators are controversial — sudden cardiac death is more often pulseless electrical activity (electromechanical dissociation) than ventricular tachyarrhythmia, and ICD shocks may not improve survival; consider on case-by-case basis.
Aortic Stenosis Coexistence and TAVR
Approximately 16% of low-flow low-gradient aortic stenosis cases harbor cardiac amyloidosis. Patients with both diseases benefit from TAVR but have lower survival than AS-only patients. Screening TTR-PYP scan should be considered in all elderly patients with low-flow low-gradient AS before structural valve intervention.
Cardiac Transplantation
Heart transplantation is rarely performed for AL amyloidosis (high recurrence in graft from underlying plasma cell dyscrasia) but ATTR cardiac amyloidosis can be considered, especially in young ATTRv patients with severe heart failure. Combined heart-liver transplant historically used for ATTRv but largely supplanted by TTR silencers.
Pearls and Pitfalls
Pearl 1 — Voltage-mass discord beats sparkling
The classic granular sparkling echocardiographic appearance is now considered nonspecific with modern transducers. The single most useful echocardiographic clue is voltage-mass discordance: ECG voltage is inappropriately low for the degree of LV wall thickening on echo. Combined with apical sparing on global longitudinal strain, sensitivity exceeds 85%.
Pitfall 1 — PYP scan before monoclonal workup
Performing PYP scan before excluding AL amyloidosis is the most common diagnostic error. AL can produce false-positive PYP uptake (5–20% of cases), and missing AL leads to delayed life-saving chemotherapy. ALWAYS do SIFE + UIFE + serum free light chain ratio first, regardless of how “obvious” ATTR seems.
Pearl 2 — TTR sequencing is mandatory after every ATTR diagnosis
Even in an 80-year-old male who “obviously” has wild-type ATTR, TTR sequencing should be performed because 5–10% turn out to carry pathogenic variants with implications for relatives. V122I in African ancestry, T60A in Irish ancestry, V30M in Portuguese/Swedish/Japanese — family screening can identify pre-symptomatic carriers eligible for early intervention.
Pitfall 2 — Routine HFrEF medication regimen
Beta-blockers, ACEi/ARB, and digoxin are often poorly tolerated in cardiac amyloidosis and may worsen symptoms. Restrictive physiology with fixed stroke volume needs preserved heart rate for cardiac output; negative inotropy precipitates output failure. Verapamil and diltiazem can cause complete heart block by binding to amyloid fibrils. Diuretics, MRA, SGLT2 inhibitors, and disease-modifying therapy form the core regimen.
Pearl 3 — Anticoagulate even in sinus rhythm
Atrial mechanical dysfunction in cardiac amyloidosis produces thrombus risk independent of AF. Patients with biatrial enlargement and advanced amyloidosis may benefit from anticoagulation even in sinus rhythm. Mandatory TEE before cardioversion regardless of anticoagulation duration — LAA thrombus prevalence is 30% in amyloid AF.
Pitfall 3 — Discontinuing tafamidis too early
Tafamidis benefit emerges at 18 months and continues to grow over years. Patients sometimes stop the drug after 6–12 months of “no improvement” — but the goal is slowing progression, not improvement. Counsel patients that benefit is measured over years and that stable clinical status on tafamidis represents successful therapy.
Pearl 4 — Bilateral carpal tunnel is a key red flag
Bilateral carpal tunnel syndrome can precede cardiac amyloidosis by 5–10 years. Asking about prior carpal tunnel surgery (often forgotten by the patient) in any elderly HFpEF patient adds substantial diagnostic yield. Some centers now recommend amyloid screening in patients undergoing bilateral carpal tunnel release after age 60.
Pitfall 4 — Missing AL in young patients
AL amyloidosis can present at age 40–60 and is rapidly fatal without treatment. Cardiac amyloidosis in any patient under 70, in patients of non-African ancestry, or in patients with proteinuria, neuropathy, periorbital purpura, or macroglossia must be presumed AL until proven otherwise. Same workup applies — but urgency is much greater.
Frequently Asked Questions
When to refer or escalate
Refer to a tertiary amyloidosis center when: PYP scan is equivocal (grade 1) or imaging-clinical findings discordant; monoclonal workup is positive (urgent hematology); ATTR variant identified (genetics + family screening); patient is candidate for TTR silencer or ASCT; aortic stenosis coexists and TAVR is being considered; conduction disease requires device decision; or transplant evaluation is being considered. Multidisciplinary amyloidosis programs (cardiology, hematology, neurology, genetics) substantially improve outcomes through coordinated care.
- Myocarditis: Diagnosis, Endomyocardial Biopsy, Cardiac MRI, and Treatment
- ST-Elevation Myocardial Infarction — Emergency Diagnosis and Reperfusion Therapy
- Stable Ischemic Heart Disease: Diagnosis and Optimal Medical Therapy
- Cardiac Tamponade: Beck’s Triad, Echocardiographic Diagnosis, and Emergency Pericardiocentesis Technique
- Heart Failure with Preserved Ejection Fraction: Diagnosis and Management
- Aortic Regurgitation: ACC/AHA Diagnosis, Echo Severity Grading, and Surgical Timing